Ten-year clinical outcomes from a randomized trial comparing new-generation everolimus-eluting stent versus first-generation Sirolimus-eluting stent: Results from the RESET extended study.
Hiroki ShiomiKen KozumaTakeshi MorimotoKazushige KadotaKengo TanabeYoshihiro MorinoToshihiro TamuraMitsuru AbeSatoru SuwaYoshiaki ItoMasakazu KobayashiKazuoki DaiKoichi NakaoYasuhiro TarutaniRyoji TaniguchiHideo NishikawaYoshito YamamotoTomohiro YamasakiAtsunori OkamuraYoshihisa NakagawaKenji AndoKoichi KobayashiKazuya KawaiKiyoshi HibiTakeshi Kimuranull nullPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2023)
During 10-year of follow-up, the risks for primary efficacy and safety endpoints were not significantly different between new-generation EES and first-generation SES, although EES compared with SES was associated with a lower risk for composite endpoints such as TLF and TVF.
Keyphrases